Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Ixabepilone. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ixabepilone. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ixabepilone. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ixabepilone. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ixabepilone. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ixabepilone. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ixabepilone. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixabepilone. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ixabepilone. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ixabepilone. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ixabepilone. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Ixabepilone. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Ixabepilone. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Ixabepilone. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixabepilone. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Ixabepilone. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixabepilone. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Ixabepilone. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Ixabepilone. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ixabepilone. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ixabepilone. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Ixabepilone. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ixabepilone. |
| Cladribine | Ixabepilone may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Ixabepilone. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Ixabepilone. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Ixabepilone. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ixabepilone. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ixabepilone. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Ixabepilone. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Ixabepilone. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Ixabepilone. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Ixabepilone. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Ixabepilone. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ixabepilone. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Ixabepilone. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ixabepilone. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Ixabepilone. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ixabepilone. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Ixabepilone. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Ixabepilone. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Ixabepilone. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ixabepilone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ixabepilone. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ixabepilone. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Ixabepilone. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Ixabepilone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ixabepilone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ixabepilone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ixabepilone. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Ixabepilone. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ixabepilone. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ixabepilone. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Ixabepilone. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Ixabepilone. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ixabepilone. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Ixabepilone. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Ixabepilone. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Ixabepilone. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ixabepilone. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ixabepilone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ixabepilone. |
| Thalidomide | The metabolism of Ixabepilone can be increased when combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Ixabepilone. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Ixabepilone. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Ixabepilone. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Ixabepilone. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ixabepilone. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ixabepilone. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Ixabepilone. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Ixabepilone. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Ixabepilone. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Ixabepilone. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Ixabepilone. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Ixabepilone. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Ciclesonide is combined with Ixabepilone. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Ixabepilone. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ixabepilone. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Ixabepilone. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Ixabepilone. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Ixabepilone. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Ixabepilone. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Pirfenidone. |
| Belinostat | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Belinostat. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Interferon alfa. |
| Glatiramer | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Glatiramer. |
| Briakinumab | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Briakinumab. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Human interferon omega-1. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Mepolizumab. |
| Abetimus | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Abetimus. |
| Belatacept | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Belatacept. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Pralatrexate. |
| Wortmannin | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Wortmannin. |
| Eribulin | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Eribulin. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Ruxolitinib. |
| Belimumab | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Belimumab. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Teriflunomide. |
| Ponatinib | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Ponatinib. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Dimethyl fumarate. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Obinutuzumab. |